Varnitrip
Utilised to manage nicotine addiction to alleviate physical cravings and support long-term smoking cessation.
- Category
- Addiction Recovery
- Active ingredient
- Varenicline
- Route
- Oral use
- Form
- Tablet
- Strengths
- 0.5mg · 1mg
Prescription and consultation requirements for Varnitrip vary by destination and are determined by the fulfilment partner.
Varnitrip details
- Condition
- Smoking Cessation
- Alternative names
- varenicline
- Therapeutic class
- Partial Nicotinic Acetylcholine Receptor Agonist
- Pharmacological class
- Smoking Cessation Agent
- Contraindications
- history of severe psychiatric disorders; severe renal impairment
- Minor side effects
- nausea; headache; insomnia
- Moderate side effects
- vivid dreams; flatulence; fatigue
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Tripada Healthcare
- Onset Time
- 1–2 weeks
- Duration
- 12–24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Alcohol
- Age restrictions
- Approved for adults over eighteen years.
Serious side effects
severe depression and suicidal ideation, requires immediate medical attention; seizure activation, requires immediate medical attention
Patient summary
utilised to manage nicotine addiction to alleviate physical cravings and support long-term smoking cessation.
Mechanism of action
Binds selectively to neuronal alpha-4-beta-2 nicotinic receptors, exerting partial agonist effects to block nicotine reward mechanisms.
Pregnancy and breastfeeding
TGA Category C: Use if potential benefits outweigh risks. Breastfeeding: Consult a clinician.